Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Regulatory November 30, 2022Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period
-
Regulatory November 21, 2022Vivesto appoints Erik Kinnman as CEO
-
Regulatory November 21, 2022Nomination Committee appointed for the 2023 Annual General Meeting in Vivesto
Vivesto published its Q3 report for 2022 on November 17, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
We published our Q2 results today, which show continued cost control, with a reduction in operating expenses.
#oncology #biotech
Interim report for the period January 1, 2022 – June 30, 2022 - Vivesto
SIGNIFICANT EVENTS DURING THE SECOND QUARTER In April Daniel Tesfa was appointed Chief Medical Officer. In April Vivesto signed an agreement with...
www.vivesto.com
For #investors and #media:
Today Inceptua launched Apealea® in Germany. This is great news for patients but also for Vivesto’s business as we are eligible for royalties on any sales.
#oncology #biotech
Vivesto notes the launch of Apealea® in Germany by Inceptua - Vivesto
Solna, Sweden, 15 August 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, is pleased to note...
www.vivesto.com
This #MensHealthWeek have a look at this campaign by @menshealthforum all about how to carry out a MAN-MOT. Your car gets one regularly so why not all men? This article shows how to do your own and help early diagnosis of Prostate cancer.
Read more here:
DIY Man MOT
Your car gets one regularly but what about you? No, not a parking ticket, an MOT. Giving your body a once-over...
bit.ly